Clarity Pharmaceuticals Ltd (ASX:CU6)

Market Cap	837.58M +17.9%
Revenue (ttm)	10.58M -1.8%
Net Income	-96.35M
EPS	-0.28
Shares Out	372.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,809,063
Open	2.330
Previous Close	2.310
Day's Range	2.250 - 2.370
52-Week Range	1.970 - 5.870
Beta	1.17
Analysts	Strong Buy
Price Target	7.13 (+216.89%)
Earnings Date	Jun 10, 2026

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 88
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CU6

Financial Performance

In fiscal year 2025, Clarity Pharmaceuticals's revenue was 9.46 million, a decrease of -17.76% compared to the previous year's 11.51 million. Losses were -64.30 million, 51.9% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for CU6 stock is "Strong Buy." The 12-month stock price target is $7.13, which is an increase of 216.89% from the latest price.

Price Target

$7.13

(216.89% upside)

Analyst Consensus: Strong Buy